Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 6/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.61 |
| ▸ | RAB9A | P51151 | 6/20 | 0.61 |
| ▸ | NPC1 | O15118 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 5/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.61 |
| ▸ | ALPL | P05186 | 1/20 | 0.61 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.57 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 4/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | MEN1 | O00255 | 3/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.51 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791688 | 0.89 | PTPN1 (0.69) | PTPN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2793238 | 0.89 | PTPN1 (0.65) | PTPN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2793299 | 0.87 | PTPN1 (0.66) | PTPN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2790995 | 0.86 | MAPT (0.67) | MAPTSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL9988447 | 0.86 | NPC1 (0.61) | MAPTSMN1; SMN2RAB9ANPC1HPGD | |
| SCHEMBL2817268 | 0.84 | MAPK1 (0.47) | PTPN1MAPTSMN1; SMN2RAB9ANPC1 | |
| SCHEMBL2792239 | 0.84 | MAPK1 (0.69) | MAPTSMN1; SMN2RAB9ANPC1ALDH1A1 | |
| SCHEMBL2842399 | 0.76 | MAPT (0.58) | MAPTSMN1; SMN2HPGDALDH1A1GAA | |
| SCHEMBL2791913 | 0.76 | PTPN1 (0.69) | PTPN1SMN1; SMN2RAB9ANPC1DYRK1A | |
| SCHEMBL17776540 | 0.75 | PDPK1 (0.72) | PTPN1MAPTSMN1; SMN2RAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-9012481-B2 | Benzoarylureido compounds, and composition for prevention or treatment of neurodegenerative brain disease containing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2015-04-21 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2011-12-29 | — | — | US | disclosed |
| WO-2010077068-A2 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2010-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319456-A1 | BENZOARYLUREIDO COMPOUNDS, AND COMPOSITION FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE BRAIN DISEASE CONTAINING THE SAME | HTT, PSEN1, PYGB | PTPN1 4064/4885MAPT 8/4885SMN1; SMN2 186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.